Konstanz, Germany, November 29, 2016 and Osaka, Japan, November 30, 2016 – Takeda Pharmaceuticals Company Limited, (“Takeda”) today announced that it will invest more than 100 Million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.
In Germany alone, several hundred thousand patients are given an artificial hip, knee or shoulder joint every year. Prof. Dr. Jan Philippe Kretzer and his team of researchers in the Laboratory of Biomechanics and Implant Research at the University Hospital in Heidelberg are studying what limits the longevity of implants and how durability can be improved.
Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines made from pure compounds.
The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.